Your browser doesn't support javascript.
loading
Efficacy and safety of bempedoic acid in patients with and without metabolic syndrome: Pooled analysis of data from four phase 3 clinical trials.
Shapiro, Michael D; Taub, Pam R; Louie, Michael J; Lei, Lei; Ballantyne, Christie M.
Affiliation
  • Shapiro MD; Center for Prevention of Cardiovascular Disease, Wake Forest University School of Medicine, Winston-Salem, NC, USA. Electronic address: mdshapir@wakehealth.edu.
  • Taub PR; Department of Cardiovascular Medicine, University of California San Diego School of Medicine, La Jolla, CA, USA.
  • Louie MJ; Esperion Therapeutics, Inc., Ann Arbor, MI, USA.
  • Lei L; Esperion Therapeutics, Inc., Ann Arbor, MI, USA.
  • Ballantyne CM; Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
Atherosclerosis ; 378: 117182, 2023 08.
Article in En | MEDLINE | ID: mdl-37517922
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hydroxymethylglutaryl-CoA Reductase Inhibitors / Metabolic Syndrome / Hypercholesterolemia / Anticholesteremic Agents Type of study: Clinical_trials / Diagnostic_studies / Guideline Limits: Humans Language: En Journal: Atherosclerosis Year: 2023 Document type: Article Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hydroxymethylglutaryl-CoA Reductase Inhibitors / Metabolic Syndrome / Hypercholesterolemia / Anticholesteremic Agents Type of study: Clinical_trials / Diagnostic_studies / Guideline Limits: Humans Language: En Journal: Atherosclerosis Year: 2023 Document type: Article Country of publication: